How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Bank of America is spending 250M annually on GLP-1 weight loss drugs. Meanwhile, Novo Nordisk, the Danish company that created a highly lucrative drug, has lost its market lead. Eli Lilly from America successfully outmaneuvered Novo Nordisk to take control of the diet-drug market. This shift raises questions regarding Europe's ability to compete within the high-stakes global economy as the competition for dominance in the GLP-1 weight-loss drug sector intensifies between these major pharmaceutical entities.